Disclosures: Yousif Alyousifi: Nothing to Disclose, Chinmay Raut: Nothing to Disclose, Antonino Oliveri: Nothing to Disclose, Vincent Chen: AstraZeneca: site PI on industry-sponsored trial, Ipsen: site co-I on industry-sponsored trial, Kowa: site co-I on industry-sponsored trial, Elizabeth Speliotes: Nothing to Disclose 2562 DEVELOPMENT OF MUTATED B-CATENIN GENE SIGNATURE (MBGS) TO IDENTIFY CTNNB1 MUTATIONS FROM WHOLE AND SPATIAL TRANSCRIPTOMIC DATA IN PATIENTS Brandon Lehrich 1 Junyan Tao 1 Silvia Liu 1 Theo Hirsch 2 Tyler Yasaka 1 Catherine Cao 1 Evan Delgado 1 Yuqing Liu 1 Xiangnan Guan 3 Shan Lu 3 Long Pan 2 Sucha Singh 1 Minakshi Poddar 1 Aatur Singhi 4 Jessica Zucman-Rossi 5 Yulei Wang 3 Satdarshan (Paul) Monga 1 , 1 University of Pittsburgh, 2 Centre de Recherche des Cordeliers, Universit Paris Cit, Sorbonne Universit, Inserm, F-75006 Pari, 3 Translational Medicine, Genentech Inc., San Francisco, CA, USA, 4 Department of Pathology, UPMC, 5 French Institute of Health and Medical Research/Inserm Background: Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related death
doi: 10.2337/db14-0302 37 BurmeisterMAAyalaJDruckerDJAyalaJE
When asked what theyd be willing to give up to afford a GLP-1 prescription, 38% said dining out or takeout, 24% said travel or leisure, and 22% said streaming subscriptions
The specific decision of how to handle any individual missed dose belongs in a conversation with your prescribing clinician
Epub 2016 May 2
